Wegovy Denied by Insurance? Fight Back — Appeal Guide (2026)

Wegovy (semaglutide 2.4mg) has FDA approval for chronic weight management and cardiovascular risk reduction — but insurance coverage remains inconsistent, and Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization denials are extremely common. This guide explains how to build a winning appeal.

Understanding Wegovy Coverage

Wegovy is not simply a "diet drug" — it is FDA-approved for:

1. Chronic weight management in adults with BMI ≥30, or ≥27 with weight-related comorbidity (2021 approval)
2. Cardiovascular risk reduction in adults with overweight/obesity and established cardiovascular disease (2024 approval, based on SELECT trial)

The cardiovascular indication is critical for appeals: if your patient has heart disease and overweight/obesity (even with BMI below 30), Wegovy can be argued as a cardiovascular medication, not a weight loss drug.

Most Common Denial Reasons

Plan Exclusion of Anti-Obesity Medications

Many employer-sponsored plans historically excluded AOMs entirely. This is changing, but if your plan documents say "weight loss drugs are excluded," the coverage battle begins with the plan itself.

What to check: Request your Summary Plan Description (SPD). Look specifically for the AOM exclusion language. If the exclusion says "weight loss drugs" but your physician's indication is "cardiovascular risk reduction" per the 2024 FDA label, the exclusion may not apply.

BMI Below Threshold or Not Documented

Your PA request must include current, documented BMI. Some denials occur because the PA was submitted without BMI values or current weight measurements.

Comorbidity Not Documented

For BMI 27–29.9, a qualifying comorbidity must be specifically documented in the PA. A physician note saying "patient needs to lose weight" is insufficient — the comorbidity (e.g., "hypertension, currently on lisinopril 10mg") must be explicit.

Step Therapy — Lifestyle Intervention First

Many plans require documentation of participation in a behavioral weight management program before approving pharmacotherapy. Some require 6 months of documented attempts. If you've been working with a dietitian or enrolled in a structured program, get that documentation.

Formulary Restriction

Some plans have preferred AOMs (e.g., Saxenda/liraglutide, Contrave/bupropion-naltrexone, Qsymia) and require step therapy within the AOM class before approving Wegovy.

Clinical Evidence for Your Appeal

SELECT trial (NEJM 2023): Semaglutide 2.4mg reduced MACE (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% in 17,604 adults with overweight/obesity and CVD. No diabetes required. This formed the basis of the 2024 FDA label update.

STEP trials: Wegovy achieved 14.9% mean body weight reduction in STEP 1 (general obesity population), significantly outperforming older AOMs.

AHA/ACC Guidelines: Weight management is now a recognized cardiovascular intervention. The 2022 AHA/ACC obesity guidelines recommend GLP-1 agonists as effective pharmacotherapy.

AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm: Recommends GLP-1 agonists in patients with obesity and cardiometabolic risk.

Building Your Appeal

Documentation to Include

1. Current BMI with weight and height (dated within 90 days)
2. Qualifying comorbidity documentation: diagnosis, medications, lab values
3. Prior lifestyle interventions: dates, programs, outcomes (or statement explaining barriers)
4. Prescribing physician letter addressing:
   • FDA-approved indication being prescribed for
   • Clinical justification vs. alternatives on the formulary
   • If CVD present: cite the SELECT trial and the 2024 cardiovascular indication
5. If plan excludes AOMs: challenge the exclusion based on cardiovascular indication separate from weight loss

For Cardiovascular Risk Reduction Appeals

If the patient has established CVD (prior MI, stroke, peripheral artery disease, or high-risk coronary artery disease) and BMI ≥27, frame the appeal around the 2024 FDA indication:

"This request is for cardiovascular risk reduction per FDA-approved Wegovy labeling (2024), based on the SELECT trial demonstrating 20% reduction in MACE. The cardiovascular indication is independent of any weight loss exclusion in the plan documents."

External Independent Review: Complete Guide" class="auto-link">External Review

For Wegovy denials, external review is often favorable. External reviewers are clinicians — often cardiologists, endocrinologists, or obesity medicine specialists — who understand the evidence base better than insurance medical reviewers.

Request external review within 60 days of final internal denial.

Get Your Wegovy Appeal Letter

ClaimBack generates a professional Wegovy appeal letter citing the SELECT trial, FDA cardiovascular indication, your insurer's specific AOM coverage criteria, and medical necessity documentation standards.

Start your Wegovy appeal at ClaimBack →

Related Reading:

• Ozempic Denied by Insurance? How to Appeal
• Mounjaro Denied? Complete Appeal Guide
• GLP-1 Drugs and Insurance: Complete Coverage Guide
• Prior Authorization Denied: Step-by-Step Appeal Guide